News

COVID-19.info

Popularization of research advances on COVID-19

Vaccines

Large-scale studies over-estimate vaccination coverage

In the fight against COVID-19, public health officials rely on surveillance data that is either collected physically (during a visit to the doctor, for example) or through on-line surveys. Small-scale studies carry the risk of targeting an unrepresentative sample of the population, while large-scale surveillance is potentially more useful, since it enables, through specific statistical […]

Read more...

Do vaccines neutralise Omicron?

The vaccines now available against COVID-19 were created using the spike surface viral protein from the original Wuhan strain. The new Omicron variant carries a much higher number of mutations than other variants, especially in the S protein. There are therefore grounds to fear that it can escape antibodies produced by current vaccines. In this […]

Read more...
Read more...

CoVac-1, a promising candidate vaccine

One of the solutions against the SARS-CoV-2 virus, which is responsible for COVID-19, is vaccines that are able to confer long-lasting immunity, especially in sectors of the population at high risk from complications. Currently available vaccines bring about a strong neutralising antibody response. But T lymphocytes also play an important role in antiviral defences by […]

Read more...

Does vaccine efficacy depend on antibody levels?

In the fight against the COVID-19 pandemic it is important to have a varied arsenal of safe and effective vaccines. Since global demand is high, prices must remain low enough to ensure equitable worldwide distribution. To complicate matters, we do not have data on vaccine efficacy for certain sectors of the population (pregnant women, children, […]

Read more...

The non-coding region of the mRNA of the Curevac vaccine has been optimised

Unlike other mRNA vaccines, the CVnCoV developed by CureVac does not use pseudouridine or nucleoside modification. The mRNA of the SARS-CoV-2 spike, which enables viral entry and is the main target of neutralising antibodies, is encapsulated in lipid nanoparticles in its stabilized pre-fusion form. Its efficacy has been evaluated in the HERALD (phase 2b/3) clinical […]

Read more...

Is the approach to anti-COVID-19 vaccination comparable to other anti-flu campaigns?

The majority of vaccines against respiratory infections are effective against symptomatic cases, but do not completely block infection. In the case of COVID-19, first results showed that the mRNA vaccines were very effective against symptomatic and asymptomatic infections, as well as against transmission. This news raised hopes that anti-SARS-CoV-2 vaccines could stop the spread of […]

Read more...

Simultaneous vaccine against COVID-19 and flu

Vaccination against SARS-CoV-2 has enabled the prevention of numerous cases of COVID-19, and numerous deaths. But this process of mass vaccination takes its toll on health systems since it involves many health professionals. In several countries, vaccination against COVID-19 is given at the same time as vaccination against winter flu. This latter is important since […]

Read more...

Moderna and Pfizer-Biontech vaccines against the Delta variant in Qatar

In Qatar, the SARS-CoV-2 Alpha variant and then the Beta variant, were at the origin of two major epidemic waves at the beginning of 2021. It was later, in March, that the Delta variant was detected. It then spread throughout the country and was responsible for 43% of infections up to September. However, the vaccination […]

Read more...

The efficacy of the vaccine against Delta

The Pfizer-BioNTech mRNA vaccine protects against infections, hospitalisations and severe cases of COVID-19. It reduces viral load and therefore reduces the infectiousness of the individual, thus hampering the virus’ spread. In Israel, SARS-CoV-2 had been largely eradicated between April and June 2021, but then the epidemic began to progress again. Israel, in common with other […]

Read more...
error: Content is protected !!